We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously

By LabMedica International staff writers
Posted on 01 May 2026

Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. More...

Multiplex testing typically depends on multiple enzymes or fluorophores and multistep workflows that burden clinical laboratories. Faster, simpler methods that can detect several RNA viruses in a single reaction would improve throughput and triage. Now, a novel diagnostic technology enables simultaneous identification of multiple viruses and variants by measuring the reaction speed of CRISPR gene scissors.

Korea Advanced Institute of Science and Technology (KAIST), with collaborators at the University of California, Berkeley, and the Gladstone Institutes, have developed an RNA diagnostic approach termed kinetic barcoding. The system uses the CRISPR-based protein called Cas13, which becomes activated upon target recognition and then cleaves surrounding RNA to generate a fluorescent signal. By differentiating targets based on cleavage speed, the method eliminates the need for multiple nucleases typically required by existing CRISPR-based technologies.

At the single-molecule level inside microdroplets, distinct reaction-speed patterns arise for each guide RNA and target RNA combination, enabling barcode-like classification. Guide RNA is an RNA molecule that directs the gene-editing system to a specific target by providing the necessary positional information. The researchers tuned these kinetics by modifying guide RNA design, allowing scalable, simultaneous detection across a wide range of viruses. Because Cas13 directly interrogates RNA, the workflow omits reverse transcription, reducing steps compared with conventional approaches.

In testing on actual clinical samples, the approach distinguished multiple respiratory viruses and SARS‑CoV‑2 variants within a single reaction. The researchers note that using a single type of nuclease to resolve multiple infections reduces system complexity while maintaining multiplex capability. The work was published on March 31, 2026, in Nature Biomedical Engineering under the title “Programmable kinetic barcoding for multiplexed RNA detection with Cas13a.”

“This study goes beyond simply determining whether a virus is present, and is the first case to use the reaction speed of gene scissors as a new form of diagnostic information. It will become a next-generation platform capable of diagnosing various infectious diseases at once in the field,” said Professor Sungmin Son, Department of Bio and Brain Engineering, KAIST.

Related Links
KAIST


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.